| Evaluating the Pharmacokinetics and Safety of Miricorilant (NCT07553663) | Corcept Therapeutics | 2026-04-30 |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (NCT07259317) | Corcept Therapeutics | 2026-01-27 |
| Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (NCT07276373) | Corcept Therapeutics | 2026-01-16 |
| Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects (NCT07240116) | Corcept Therapeutics | 2025-09-11 |
| Evaluation of Miricorilant on Liver Fat in Patients With MASLD (NCT06947304) | Corcept Therapeutics | 2025-08-22 |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (NCT06906341) | Corcept Therapeutics | 2025-04-11 |
| Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM) (NCT06829537) | Corcept Therapeutics | 2025-03-28 |
| Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant (NCT06928779) | Corcept Therapeutics | 2024-10-08 |
| Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants (NCT06495944) | Corcept Therapeutics | 2024-05-31 |
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) (NCT06108219) | Corcept Therapeutics | 2023-10-25 |
| Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) (NCT05772169) | Corcept Therapeutics | 2023-03-31 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant (NCT05712265) | Corcept Therapeutics | 2023-01-24 |
| Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (NCT05407324) | Corcept Therapeutics | 2022-11-15 |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (NCT05257408) | Corcept Therapeutics | 2022-06-29 |
| Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants (NCT05347979) | Corcept Therapeutics | 2022-05-25 |
| A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) (NCT05320146) | Corcept Therapeutics | 2022-03-04 |
| Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant (NCT05553470) | Corcept Therapeutics | 2022-03-03 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) (NCT05117489) | Corcept Therapeutics | 2021-11-23 |
| Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants (NCT04990310) | Corcept Therapeutics | 2021-08-18 |
| Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants (NCT05003713) | Corcept Therapeutics | 2021-08-03 |
| Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants (NCT04994743) | Corcept Therapeutics | 2021-07-13 |
| T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers (NCT04795479) | Corcept Therapeutics | 2021-01-22 |
| Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) (NCT03823703) | Corcept Therapeutics | 2020-11-04 |
| Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants (NCT04672512) | Corcept Therapeutics | 2020-10-23 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) (NCT04373265) | Corcept Therapeutics | 2020-09-30 |
| A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects (NCT06094738) | Corcept Therapeutics | 2020-09-19 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) (NCT04524403) | Corcept Therapeutics | 2020-09-09 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (NCT04308590) | Corcept Therapeutics | 2020-07-27 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (NCT04329949) | Corcept Therapeutics | 2020-06-30 |
| Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants (NCT04672499) | Corcept Therapeutics | 2020-04-27 |
| Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants (NCT04249323) | Corcept Therapeutics | 2020-01-27 |
| A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant (NCT06094725) | Corcept Therapeutics | 2020-01-06 |
| A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications (NCT03818256) | Corcept Therapeutics | 2019-12-04 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03776812) | Corcept Therapeutics | 2019-04-05 |
| The Effect of CORT118335 on Olanzapine-Induced Weight Gain (NCT03877562) | Corcept Therapeutics | 2019-04-01 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (NCT03697109) | Corcept Therapeutics | 2018-11-15 |
| Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants (NCT03877952) | Corcept Therapeutics | 2018-09-13 |
| Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants (NCT03878264) | Corcept Therapeutics | 2018-08-06 |
| A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants (NCT03540836) | Corcept Therapeutics | 2018-05-24 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome (NCT03604198) | Corcept Therapeutics | 2018-05-07 |
| Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites (NCT03512548) | Corcept Therapeutics | 2018-04-10 |
| Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s (NCT03457597) | Corcept Therapeutics | 2018-03-06 |
| Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT03437941) | Corcept Therapeutics | 2018-02-20 |
| Relacorilant Food Effect Study in Healthy Subjects (NCT03442621) | Corcept Therapeutics | 2018-01-16 |
| CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) (NCT03335956) | Corcept Therapeutics | 2017-09-21 |
| Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome (NCT03379363) | Corcept Therapeutics | 2017-09-18 |
| First-in-human Study in Healthy Subjects (NCT03315338) | Corcept Therapeutics | 2017-09-15 |